Tenderwize
Wróć do wyszukiwania

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2028 · 642 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of discount contracts for Infliximab (subcutaneous injection) with multiple pharmaceutical entrepreneurs.
  • Uniform contract terms; no individual negotiations.
Pokaż pełne podsumowanie

Open-House procedure for discount contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Infliximab (subcutaneous injection). No competitive selection; any qualified pharmaceutical entrepreneur can join. No estimated value provided. The lead buyer is Techniker Krankenkasse, with several other German statutory health insurance funds. The contract term is up to 24 months starting June 1, 2026, ending May 31, 2028. Participation is open throughout the contract term. No procurement documents were analyzed.

Ryzyka

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product or be entitled to place the product on the market.

Administrative

  • Must provide a self-declaration on authorization and company (Anlage 4).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Conclusion of discount contracts for the active substance Infliximab (subcutaneous injection) with any eligible pharmaceutical entrepreneur under an open-house model. No exclusivity; uniform conditions apply.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Termin

Deadline May 30, 2028

Szczegóły zamówienia

Data publikacji
19 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
266368-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3